#United States #New York #Faruqi & Faruqi #PEPG #PepGen

Faruqi & Faruqi Initiates Investigation Regarding PepGen Inc.

Faruqi & Faruqi, LLP, a prominent national securities law firm based in the United States, has embarked on an investigation into potential claims against PepGen Inc. This inquiry is primarily focused on the concerns raised by investors who have faced losses exceeding $50,000 between March 7, 2024, and March 3, 2025. The firm is urging these investors to reach out and discuss their legal rights and options to potentially recover their losses.

Background of the Investigation

The investigation follows several troubling developments concerning PepGen’s clinical trials and financial disclosures. The firm, with its reputation for advocating for investors’ rights since its establishment in 1995, has vowed to ensure that affected investors receive the attention and representation they deserve. With offices located in key states such as New York, California, and Georgia, Faruqi & Faruqi has historically secured hundreds of millions of dollars in settlements for its clients.

On July 30, 2024, PepGen reported clinical data from its ongoing CONNECT1 study, announcing that the PGN-EDO51 treatment achieved only modest results. Despite hopes of positive outcomes, analysts voiced disappointment as the increase in dystrophin levels noted fell below earlier expectations. Following the announcement, PepGen’s stock price depreciated significantly, indicating investor discontent and rising concerns about the company’s prospects.

The situation grew more precarious for PepGen when it received a clinical hold notice from the FDA on December 16, 2024, raising flags about the safety of its CONNECT2 trial. This led to another drop in the company’s stock price, emphasizing the potential implications of these regulatory issues. Investors were understandably worried when PepGen highlighted safety concerns and paused participant enrollment in light of the FDA’s heightened scrutiny.

Key Events for PepGen Investors

Throughout 2025, PepGen faced numerous challenges that prompted further investor concern. A press release from January 29 revealed significant safety issues in the CONNECT1 study, resulting in changes to dosing protocols and communications with agencies such as Health Canada.

On March 4, 2025, PepGen announced its decision to temporarily halt the CONNECT2 study, citing the need for a thorough review of ongoing trial results. Sadly, the announcements continued to worsen, as a May 28 press release declared that PGN-EDO51 did not reach desired dystrophin targets, resulting in the discontinuation of its development for Duchenne Muscular Dystrophy (DMD). The ramifications of these announcements were stark, with share prices plummeting further, underscoring a significant erosion of investor confidence.

Call to Action for Affected Investors

Faruqi & Faruqi is now encouraging any investor who suffered losses exceeding the $50,000 mark to connect with Josh Wilson, one of the firm’s partners directly. Those impacted can dial either 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their situations confidentially. The firm emphasizes that not participating in this action does not eliminate one’s ability to claim recovery should a favorable settlement or ruling ensue.

Investors who believe they may have relevant information or insights regarding PepGen’s operational or financial practices are urged to reach out to Faruqi & Faruqi. This includes whistleblowers, former staff members, and other shareholders who may assist in building a case that could lead to significant repercussions for PepGen and its executives.

The opportunity to reclaim losses exists through legal avenues, and while there’s no guarantee of specific recoveries, those who choose to act promptly may stand to benefit significantly from any future developments in this ongoing matter.

Pouring resources into understanding the full scope of PepGen’s actions will allow investors to hold the company accountable. For up-to-date information regarding this class action lawsuit, individuals can navigate the law firm’s website or follow their ongoing communications through various social media platforms.

As this investigation unfolds, stakeholders will be watching closely to see how PepGen responds and addresses the myriad of challenges it faces in maintaining investor trust and regulatory compliance.